Literature DB >> 10739703

Development and assessment of a general theory of cervical carcinogenesis utilizing a severe combined immunodeficiency murine-human xenograft model.

K S Tewari1, J A Taylor, S Y Liao, P J DiSaia, R A Burger, B J Monk, C C Hughes, L P Villarreal.   

Abstract

OBJECTIVE: Currently, we lack a theoretical explanation for why squamous cell cervical cancer develops predominantly in specific sites (i.e., along the squamocolumnar junction). We therefore implanted human cervical tissues containing the transformation zone in severe combined immunodeficiency (SCID) mice and studied morphology, steroid effects, gene expression, and human papillomavirus (HPV) factors.
METHODS: Normal and dysplastic human cervical tissues (3 x 2 mm) were placed subcutaneously in SCID-beige mice and later assessed by in situ hybridization for HPV 16/18 DNA and by immunohistochemistry for expression of CD31, keratin, proliferating-cell nuclear antigen, HPV 16 E6, p53, and Notch-1 (a binary cell fate determination protein). Some normal tissues were implanted with either a 90-day release 1.7-mg 17beta-estradiol pellet or a 5-mg tamoxifen pellet; others were infected prior to implantation with human recombinant adenovirus 5 vector containing a human cytomegalovirus promoter-driven beta-galactosidase gene and later assessed by X-gal staining.
RESULTS: Murine and human vessels formed anastomoses by 3 weeks. For at least 11 weeks, normal tissue retained the transformation zone and normal cell-type-specific keratin expression and exhibited normal proliferation; Notch-1 was present only in the basal cell layer. Dysplastic tissues exhibited koilocytosis, increased levels of cellular proliferation, and aberrant keratin, p53, and Notch-1 expression; HPV 16/18 DNA and HPV 16 E6 protein were detected for at least 6 weeks. Squamous metaplasia of normal cervical epithelium resulted from estrogen exposure, and a predominant columnar differentiation pattern was associated with tamoxifen administration. Through stable adenovirus infection, beta-galactosidase was expressed for at least 6 weeks.
CONCLUSIONS: This small manipulatable xenograft model maintains normal and dysplastic human cervical epithelium through neovascularization. Neoplastic tissue retains HPV 16/18 DNA and a premalignant phenotype, including elevated levels of cellular proliferation and aberrant keratin, p53, and Notch-1 expression. These attributes constitute essential features of a biologic model through which one may study HPV-mediated human disease and may be superior to cell culture and transgenic murine systems. Furthermore, this may serve as a model for gene therapy. Finally, we suggest that the normal cervical epithelium is maintained through putative interactions between the Notch locus and cell cycle growth regulators such as p53 and pRb. Neoplastic cervical epithelium may arise through disruption of this pathway. This theory may be testable in our animal model. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10739703     DOI: 10.1006/gyno.2000.5729

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  9 in total

Review 1.  Pharmacologic management of advanced cervical cancer: antiangiogenesis therapy and immunotherapeutic considerations.

Authors:  Teresa C Longoria; Krishnansu S Tewari
Journal:  Drugs       Date:  2015-11       Impact factor: 9.546

Review 2.  Evidence-Based Treatment Paradigms for Management of Invasive Cervical Carcinoma.

Authors:  Krishnansu S Tewari; Bradley J Monk
Journal:  J Clin Oncol       Date:  2019-08-12       Impact factor: 44.544

3.  Notch1-mediated tumor suppression in cervical cancer with the involvement of SST signaling and its application in enhanced SSTR-targeted therapeutics.

Authors:  Laura G Franko-Tobin; L Vienna Mackey; Wei Huang; Xiangwei Song; Baofeng Jin; Jing Luo; Lynsie M Morris; Minqiu Liu; Joseph A Fuselier; David H Coy; Lizi Wu; Lichun Sun
Journal:  Oncologist       Date:  2012-01-30

4.  Establishment of red fluorescent protein-tagged HeLa tumor metastasis models: determination of DsRed2 insertion effects and comparison of metastatic patterns after subcutaneous, intraperitoneal, or intravenous injection.

Authors:  Jau-Yeong Lu; Hui-Chun Chen; Ricky Yuan-Yuan Chu; Tsu-Chun Emma Lin; Ping-I Hsu; Ming-Shyan Huang; Ching-Jiunn Tseng; Michael Hsiao
Journal:  Clin Exp Metastasis       Date:  2003       Impact factor: 5.150

5.  Improved survival with bevacizumab in advanced cervical cancer.

Authors:  Krishnansu S Tewari; Michael W Sill; Harry J Long; Richard T Penson; Helen Huang; Lois M Ramondetta; Lisa M Landrum; Ana Oaknin; Thomas J Reid; Mario M Leitao; Helen E Michael; Bradley J Monk
Journal:  N Engl J Med       Date:  2014-02-20       Impact factor: 91.245

6.  Prospective Validation of Pooled Prognostic Factors in Women with Advanced Cervical Cancer Treated with Chemotherapy with/without Bevacizumab: NRG Oncology/GOG Study.

Authors:  Krishnansu S Tewari; Michael W Sill; Bradley J Monk; Richard T Penson; Harry J Long; Andrés Poveda; Lisa M Landrum; Mario M Leitao; Jubilee Brown; Thomas J A Reid; Helen E Michael; David H Moore
Journal:  Clin Cancer Res       Date:  2015-12-15       Impact factor: 12.531

Review 7.  Human papillomavirus and cervical cancer.

Authors:  Eileen M Burd
Journal:  Clin Microbiol Rev       Date:  2003-01       Impact factor: 26.132

8.  Therapeutic vaccination using HPV 16 E7 to eradicate CIN3.

Authors:  Krishnansu S Tewari
Journal:  J Gynecol Oncol       Date:  2019-11       Impact factor: 4.401

9.  Circulating Tumor Cells In Advanced Cervical Cancer: NRG Oncology-Gynecologic Oncology Group Study 240 (NCT 00803062).

Authors:  Krishnansu S Tewari; Michael W Sill; Bradley J Monk; Richard T Penson; David H Moore; Heather A Lankes; Lois M Ramondetta; Lisa M Landrum; Leslie M Randall; Ana Oaknin; Mario M Leitao; Eric L Eisenhauer; Paul DiSilvestro; Linda Van Le; Michael L Pearl; James J Burke; Ritu Salani; Debra L Richardson; Helen E Michael; David W Kindelberger; Michael J Birrer
Journal:  Mol Cancer Ther       Date:  2020-08-26       Impact factor: 6.261

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.